AstraZeneca and Seres Therapeutics Enters into Research Collaboration for 3yrs.

 AstraZeneca and Seres Therapeutics Enters into Research Collaboration for 3yrs.

AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58 Study for Type-2 Diabetes (T2D)

Shots:

  • Seres to receive $20M in three equal installments and have rights for targeted microbiome therapeutics for cancer immunotherapy. AZ to get an option to negotiate rights and share the development cost
  • The focus of the agreement is to develop microbiome for immuno-oncology by using Seres’ expertise in microbiome with AstraZeneca’s experience in oncology products
  • Seres’ leading microbiome candidates includes SER-109 & has received FDA’s BT & OD designation. SER-287 & SER-401 is currently being evaluated in P-II b & P-I b studies respectively

Click here to read full press release/ article | Ref: Seres Therapeutics | Image: Express

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post